Nuvation Bio: IBTROZI (taletrectinib) median DOR aktualisiert auf 50 Monate

Der Daten-Cutoff vom August 2025 zeigt, dass die mediane Dauer des Ansprechens bei TKI-naiven Patienten auf 50 Monate gestiegen ist, was eine geplante ergänzende NDA-Einreichung bis Ende 2025 unterstützt. Dies stärkt das klinische Profil des bereits zugelassenen IBTROZI bei fortgeschrittenem ROS1+ NSCLC.

Kernfakten

Eingereicht: 17. Nov. 2025, 22:31
Ereignis: FDA-Label-Update
Richtung: Positiv
Unternehmen: NUVBNuvation Bio
Asset: taletrectinib
Quelle: SEC 8-K
Belegstatus: Belegt
cORR: 89% (gepoolt)
mPFS: 46 Monate
Medianes DOR: 50 Monate

Auszug aus der Quelle

EX-99.1 2 d845081dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 DRIVEN BY SCIENCE FOCUSED ON LIFE November 2025 Forward-looking statements Certain statements included in this presentation (this “Presentation”) that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are no

SEC 8-K